Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

Prudent investors should note that the Supreme Court decision is a big gift to China as the tariffs on China are now lower than they were before the Supreme Court decision. Most portfolios are now ...

AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23, AbbVie (NYSE: ABBV) announced plans to ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient (API) manufacturing facilities at its ...

VectorCare’s Smart on FHIR allows in-EHR transport requests. Bambi is the first NEMT platform to integrate via their ...

Savannah homeowners are encouraged to schedule a pre-spring HVAC system inspection now to reduce breakdown risk during peak ...

Ready for Spring Break? Cancun All Inclusive has everything you need. All Inclusive Resorts, Airport Transportation, ...

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...